FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2980303454> ?p ?o ?g. }

• W2980303454 abstract "Abstract Abstract 617 Disappearance of normal bone marrow (BM) plasma cells (N-PC) predicts malignant transformation of monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma (SMM) into symptomatic myeloma (MM). The homing, behavior and survival of N-PC, but also CD34+ hematopoietic stem/precursor cells (HPC), B-cell precursors, and (mono)clonal/aberrant PC (M-PC) largely depends on their interaction with SDF-1 expressing BM stromal cell niches. Accordingly, it can be hypothesized that a certain degree of competition among BM B-cell precursors, CD34+ HPC, and PC exist for the same BM niches. Thus, progressive replacement of normal cells by M-PC could help to explain the occurrence of cytopenias and hypogammaglobulinemia in MM patients. However, this hypothesis has not been investigated in depth neither in MM nor in SMM and MGUS. In this study we analyze by 8-color multiparameter flow cytometry the distribution and competitive migration capacity of B-cell precursors, CD34+ HPC, N-PC and M-PC in the BM and PB of patients with MGUS (n=60), SMM (n=47) and MM (n=87) at diagnosis plus 12 MM cases studied after high-dose therapy/autologous stem cell transplantation (MM POST-HDT/ASCT) vs. healthy adults aged >60 years (HA; n=26). The percentage of BM M-PC as well as the number of M-PC from all BMPC found at diagnosis significantly (p<.001) increased from MGUS to SMM and MM patients. Circulating M-PC were also detected at diagnosis in the PB of MGUS (21%) vs. SMM (69%) and MM (75%) at increasing M-PC counts (p≤.002). Interestingly, PB vs. BM M-PC showed significantly lower amounts of sideward light scatter (p<.001), together with lower levels of CD38 (p=.001), CD40 (p=.006), CD56 (p=.03) and CD138 (p=.02) expression. Focusing on the CXCR4-SDF1 axis, we found that the proportion of CXCR4+ PC slightly decreased (p>.05) from N-PC from HA (42%) to M-PC from MGUS (39%), SMM (37%) and MM (35%) patients at diagnosis, while MM POST-HDT/ASCT cases showed the lowest values (28%). In contrast, plasma levels of SDF-1 increased from HA (1150 pg/mL) to MGUS (1352 pg/mL), SMM (1656 pg/mL) and MM (1778 pg/mL; p=.04 vs. HA) patients, returning to almost normal levels in MM POST-HDT/ASCT (1331 pg/mL). Thus, an inverse correlation trend (r2=.12; p=.05) between the proportion of CXCR4+ PC and SDF-1 plasma levels was found. Concerning the distribution of the normal cell populations, BM pro-B and pre-B cell precursors were significantly decreased in MM (p=.001) patients vs. HA, while it was normal in MGUS (p>.05) and SMM (p>.05). Despite the number of N-PC in the BM was significantly lower among MM and SMM vs. MGUS cases (p<.001), the distribution of circulating N-PC in PB was normal in all three groups of patients (p>.05 vs. HA). Interestingly however, the proportion of CXCR4+ PB N-PC progressively increased from HA (11%) to MGUS (14%), SMM (15%) and MM (21%; p=.05 vs. HA), while MM POST-HDT/ASCT cases showed the lowest median percentage of CXCR4+ PB N-PC (5%). CD34+ HPC were found to be depleted in the BM of MM (0.3%; p=.001) and SMM (0.4%; p=.002) patients vs. HA (0.9%) while MGUS (0.8%) and MM POST-HDT/ASCT (1.1%) patients showed normal CD34+ HPC numbers. Conversely, PB CD34+ HPC progressively increase from HA to MGUS, SMM and MM cases (p=.008 and p=.06 vs. HA, respectively). By contrast, in MM POST-HDT/ASCT patients the number of PB CD34+ HPC returned to normal/lower levels. Ex-vivo competition assays between BM B-cells, PC and CD34+ HPC for SDF-1 induced migration showed that in HA, CD34+ HPC displayed the highest migration potential in the presence of SDF-1, followed by pre-B cell precursors; conversely N-PC barely migrated. No significant differences were found for the migration of all cell populations analyzed between MGUS and SMM patients vs. HA, except for M-PC that showed an impaired migration in the presence of SDF-1. In turn, the migration potential of CD34+ HPC (p=.04), and pre-B cell precursors (p=.02) was markedly reduced in symptomatic MM, particularly at lower SDF-1 concentrations (30nM). Most interestingly, the migration of M-PC from symptomatic MM was markedly increased at both concentrations of SDF-1 used: median of 2.9% and 1.0% for SDF-1 concentrations of 30nM and 70nM, respectively. Overall, these findings provide evidence about the role of progressive competition and replacement of normal BM cells by M-PC in determining transformation of pre-malignant MGUS and SMM into symptomatic MM. Disclosures: No relevant conflicts of interest to declare." @default.
• W2980303454 created "2019-10-18" @default.
• W2980303454 creator A5000841982 @default.
• W2980303454 creator A5016479494 @default.
• W2980303454 creator A5029159537 @default.
• W2980303454 creator A5030136239 @default.
• W2980303454 creator A5030925049 @default.
• W2980303454 creator A5031837957 @default.
• W2980303454 creator A5032722606 @default.
• W2980303454 creator A5033127381 @default.
• W2980303454 creator A5035799376 @default.
• W2980303454 creator A5041947496 @default.
• W2980303454 creator A5047866471 @default.
• W2980303454 creator A5053474378 @default.
• W2980303454 creator A5054952877 @default.
• W2980303454 creator A5057189669 @default.
• W2980303454 creator A5057834186 @default.
• W2980303454 creator A5059635260 @default.
• W2980303454 creator A5061635867 @default.
• W2980303454 creator A5064147442 @default.
• W2980303454 creator A5065232101 @default.
• W2980303454 creator A5066949744 @default.
• W2980303454 creator A5069753479 @default.
• W2980303454 creator A5073197937 @default.
• W2980303454 creator A5075422618 @default.
• W2980303454 creator A5082983493 @default.
• W2980303454 creator A5088409474 @default.
• W2980303454 date "2010-11-19" @default.
• W2980303454 modified "2023-10-17" @default.
• W2980303454 title "Competition Between (Mono)Clonal Plasma Cells and Normal Cells for Potentially Overlapping Bone Marrow Niches Is Associated with a Progressively Altered Cellular Distribution In MGUS Vs. Myeloma" @default.
• W2980303454 doi "https://doi.org/10.1182/blood.v116.21.617.617" @default.
• W2980303454 hasPublicationYear "2010" @default.
• W2980303454 type Work @default.
• W2980303454 sameAs 2980303454 @default.
• W2980303454 citedByCount "0" @default.
• W2980303454 crossrefType "journal-article" @default.
• W2980303454 hasAuthorship W2980303454A5000841982 @default.
• W2980303454 hasAuthorship W2980303454A5016479494 @default.
• W2980303454 hasAuthorship W2980303454A5029159537 @default.
• W2980303454 hasAuthorship W2980303454A5030136239 @default.
• W2980303454 hasAuthorship W2980303454A5030925049 @default.
• W2980303454 hasAuthorship W2980303454A5031837957 @default.
• W2980303454 hasAuthorship W2980303454A5032722606 @default.
• W2980303454 hasAuthorship W2980303454A5033127381 @default.
• W2980303454 hasAuthorship W2980303454A5035799376 @default.
• W2980303454 hasAuthorship W2980303454A5041947496 @default.
• W2980303454 hasAuthorship W2980303454A5047866471 @default.
• W2980303454 hasAuthorship W2980303454A5053474378 @default.
• W2980303454 hasAuthorship W2980303454A5054952877 @default.
• W2980303454 hasAuthorship W2980303454A5057189669 @default.
• W2980303454 hasAuthorship W2980303454A5057834186 @default.
• W2980303454 hasAuthorship W2980303454A5059635260 @default.
• W2980303454 hasAuthorship W2980303454A5061635867 @default.
• W2980303454 hasAuthorship W2980303454A5064147442 @default.
• W2980303454 hasAuthorship W2980303454A5065232101 @default.
• W2980303454 hasAuthorship W2980303454A5066949744 @default.
• W2980303454 hasAuthorship W2980303454A5069753479 @default.
• W2980303454 hasAuthorship W2980303454A5073197937 @default.
• W2980303454 hasAuthorship W2980303454A5075422618 @default.
• W2980303454 hasAuthorship W2980303454A5082983493 @default.
• W2980303454 hasAuthorship W2980303454A5088409474 @default.
• W2980303454 hasConcept C10205521 @default.
• W2980303454 hasConcept C109159458 @default.
• W2980303454 hasConcept C142724271 @default.
• W2980303454 hasConcept C151872237 @default.
• W2980303454 hasConcept C153911025 @default.
• W2980303454 hasConcept C159654299 @default.
• W2980303454 hasConcept C159912055 @default.
• W2980303454 hasConcept C163864487 @default.
• W2980303454 hasConcept C16930146 @default.
• W2980303454 hasConcept C18903297 @default.
• W2980303454 hasConcept C203014093 @default.
• W2980303454 hasConcept C2776364478 @default.
• W2980303454 hasConcept C2776396001 @default.
• W2980303454 hasConcept C2777250017 @default.
• W2980303454 hasConcept C2780007613 @default.
• W2980303454 hasConcept C28328180 @default.
• W2980303454 hasConcept C502942594 @default.
• W2980303454 hasConcept C542903549 @default.
• W2980303454 hasConcept C553184892 @default.
• W2980303454 hasConcept C71924100 @default.
• W2980303454 hasConcept C86803240 @default.
• W2980303454 hasConcept C95444343 @default.
• W2980303454 hasConceptScore W2980303454C10205521 @default.
• W2980303454 hasConceptScore W2980303454C109159458 @default.
• W2980303454 hasConceptScore W2980303454C142724271 @default.
• W2980303454 hasConceptScore W2980303454C151872237 @default.
• W2980303454 hasConceptScore W2980303454C153911025 @default.
• W2980303454 hasConceptScore W2980303454C159654299 @default.
• W2980303454 hasConceptScore W2980303454C159912055 @default.
• W2980303454 hasConceptScore W2980303454C163864487 @default.
• W2980303454 hasConceptScore W2980303454C16930146 @default.
• W2980303454 hasConceptScore W2980303454C18903297 @default.
• W2980303454 hasConceptScore W2980303454C203014093 @default.
• W2980303454 hasConceptScore W2980303454C2776364478 @default.
• W2980303454 hasConceptScore W2980303454C2776396001 @default.
• W2980303454 hasConceptScore W2980303454C2777250017 @default.
• W2980303454 hasConceptScore W2980303454C2780007613 @default.
• W2980303454 hasConceptScore W2980303454C28328180 @default.
• W2980303454 hasConceptScore W2980303454C502942594 @default.

• next